Cherry, a BNPL company for medical procedures, has raised a Series C round in recent months at an over $2 billion valuation, Axios has learned.
Why it matters: BNPL companies fell out of favor coming out of the pandemic, but a new cohort of young startups in the space proves it was a revaluation, not demolition.
